Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bruce Montgomery

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
American Journal of Respiratory and Critical Care Medicine|February 1, 2024
Interstitial Lung Disease: Not So FastA Bruce Montgomery
The New England Journal of Medicine|November 6, 2004
The antibiotic pipelineA Bruce Montgomery
American Journal of Respiratory and Critical Care Medicine|June 4, 2013
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trialsDaniel M Rose, A Bruce Montgomery
Journal of Aerosol Medicine and Pulmonary Drug Delivery|October 21, 2010
Inhaled lidocaine for the treatment of asthma: lack of efficacy in two double-blind, randomized, placebo-controlled clinical studiesTammy Abuan, Melissa Yeager, A Bruce Montgomery
Current Opinion in Infectious Diseases|October 16, 2013
Aerosolized antibiotics: do they add to the treatment of pneumonia?Marin H Kollef, Cindy W Hamilton, A Bruce Montgomery
Managed Care (Langhorne, Pa.)|March 25, 2011
Health care utilization & costs for cystic fibrosis patients with pulmonary infectionsAmy K O'Sullivan, Jane Sullivan, Keiko Higuchi, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|January 4, 2014
A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patientsA Bruce Montgomery, Shirley Vallance, Tammy Abuan, et al.
Antimicrobial Agents and Chemotherapy|April 23, 2014
Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibioticsA Bruce Montgomery, Paul R Rhomberg, Tammy Abuan, et al.
Antimicrobial Agents and Chemotherapy|April 23, 2014
Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogensA Bruce Montgomery, Paul R Rhomberg, Tammy Abuan, et al.
Chest|May 19, 2009
Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infectionAlexandra L Quittner, Avani C Modi, Claire Wainwright, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
American Journal of Respiratory and Critical Care Medicine|February 1, 2024
Interstitial Lung Disease: Not So FastA Bruce Montgomery
The New England Journal of Medicine|November 6, 2004
The antibiotic pipelineA Bruce Montgomery
American Journal of Respiratory and Critical Care Medicine|June 4, 2013
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trialsDaniel M Rose, A Bruce Montgomery
Journal of Aerosol Medicine and Pulmonary Drug Delivery|October 21, 2010
Inhaled lidocaine for the treatment of asthma: lack of efficacy in two double-blind, randomized, placebo-controlled clinical studiesTammy Abuan, Melissa Yeager, A Bruce Montgomery
Current Opinion in Infectious Diseases|October 16, 2013
Aerosolized antibiotics: do they add to the treatment of pneumonia?Marin H Kollef, Cindy W Hamilton, A Bruce Montgomery
Managed Care (Langhorne, Pa.)|March 25, 2011
Health care utilization & costs for cystic fibrosis patients with pulmonary infectionsAmy K O'Sullivan, Jane Sullivan, Keiko Higuchi, et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery|January 4, 2014
A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® inline nebulizer system in mechanically ventilated patientsA Bruce Montgomery, Shirley Vallance, Tammy Abuan, et al.
Antimicrobial Agents and Chemotherapy|April 23, 2014
Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibioticsA Bruce Montgomery, Paul R Rhomberg, Tammy Abuan, et al.
Antimicrobial Agents and Chemotherapy|April 23, 2014
Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogensA Bruce Montgomery, Paul R Rhomberg, Tammy Abuan, et al.
Chest|May 19, 2009
Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infectionAlexandra L Quittner, Avani C Modi, Claire Wainwright, et al.
Pageof 4